RxDoctor Payments DataLook up a doctor →

Michael Ryan, MD

Gastroenterology · Norfolk, VANPI 1962488668

Payments from drug & device makers

$1,451,622in general payments, 2019–2025

Across 817 payments — averaging $1776.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intercept Pharmaceuticals, Inc.$512K
  • Gilead$368K
  • AbbVie$188K
  • Pfizer$153K
  • Novartis$74K
  • Ipsen Biopharmaceuticals, Inc$43K
  • plus $114K from 37 others

What the payments were for

  • Consulting fees$13,7384%
  • Speaking & faculty fees$282,50184%
  • Travel & lodging$24,6257%
  • Food & beverage$14,2774%
  • Education$300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,451,622 in reported general payments places this provider in the 95th percentile of 473 gastroenterology providers in Virginia.

See all gastroenterology providers in Virginia

Medicare billing

Part B allowed, 2024
$278,119
Medicare patients
904
Services billed
1,581

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab19$533,577
XifaxanRifaximin37$115,240
ZenpepLipase/Protease/Amylase16$71,431
MounjaroTirzepatide40$46,722
CreonLipase/Protease/Amylase18$32,081
LinzessLinaclotide38$24,570
VemlidyTenofovir Alafenamide13$19,926
Sucralfate210$16,946
Mesalamine18$13,128
Ursodiol67$12,416
Mycophenolic AcidMycophenolate Sodium11$8,354
TrulancePlecanatide12$6,862
Tacrolimus31$5,900
Colesevelam Hcl23$5,047
Mesalamine DrMesalamine17$4,761

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$375$533,57719 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$319$122,10249 claims
Aimmune Therapeutics, Inc.Zenpep$36$71,43116 claims
AbbVieCreon, Linzess$188,428$56,65156 claims
Lilly USA, LLCMounjaro$48$46,72240 claims
GileadVemlidy$367,702$19,92613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 473 gastroenterology providers in Virginia.

Other gastroenterology in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →